Resource Centers
- FDA Approves Aripiprazole to Treat Irritability in Autistic Children
- Health Care Reform May Hurt Hospital Credit
- FDA Expands Use of Maraviroc to Include Treatment-Naive HIV Patients
- Take-Back Programs and In-House Filtration Systems Reduce Pharmaceutical Pollutants and Improve Municipal Drinking Water Quality
Business of Medicine Journals
Medscape Community Resources
POLL
Concerns about the H1N1 flu vaccine have led some parents to decide not to vaccinate their child. If parents refuse to vaccinate their child with the H1N1 or another vaccine, even after discussing its advantages, is it ethical or not ethical to dismiss the child as a patient, provided that they are given plenty of notice to find another physician?
- A Treatment Option for Atrial Fibrillation
- A single medication with 4 indications
- A treatment option for ACS and DVT/PE
- ABILIFY® (aripiprazole)
- ACUVUE® Brand Contact Lenses
- ADHD treatment: Efficacy, insights, and dosing
- ALIMTA® (pemetrexed for injection)
- AMBIEN CR® (zolpidem tartrate extended-release CIV)
- Argatroban
- Atrial Fibrillation Condition Site
- COSAMIN®DS
- CRESTOR® (rosuvastatin calcium)
- Carac® (fluorouracil cream 0.5%)
- Ciprodex® (ciprofloxacin 0.3% and dexamethasone 0.1%) Sterile Otic Suspension
- Clinical Management Center
- DanActive® and ACTIVIA® Information Center
- Diabetes in America
- ENABLEX® (darifenacin) Extended-Release Tablets 7.5 mg or 15 mg
- Epilepsy360: Connections in Care
- GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant]
- GEMZAR® (gemcitabine HCI)
- GEODON® (ziprasidone HCI)
- Genomic Advances in Cardiovascular Care
- Heartmate II® Left Ventricular Assist System
- IL-6 and Rheumatoid Arthritis
- ISENTRESS® (raltegravir) Tablets
- Institute for Advances in Point-of-Care Testing
- Kidney Transplantation
- LEVAQUIN® (levofloxacin) tablets/injection
- LOVAZA® (omega-3-acid ethyl esters)
- NEW INTUNIV" (guanfacine) Extended Release Tablets
- NUCYNTA™ (tapentadol)
- NUVIGIL® (armodafinil) Tablets [C-IV]
- Navigenics® Genetic Risk Assessment Services
- Neuroendocrine tumors: Increasing in incidence and easy to overlook
- Neutrogena® Pure & Free" Baby Sunblock Lotion
- OPTIMAL Forum"
- Onglyza" (saxagliptin) InfoSite
- PEGASYS (peginterferon alfa-2a) for injection
- PREMARIN® (conjugated estrogens tablets, USP)
- PRISTIQ® (desvenlafaxine)
- ProAir® HFA
- Professional Liability Risk: Facts, Perspectives, and Management Strategies InfoSite
- QuickVue® Influenza A+B Test
- REBIF® (interferon beta-1a)
- RITUXAN® (Rituximab)
- Research VEGF: Emerging Research Around Targeting VEGF
- Risk of Osteoporosis
- SANDOSTATIN® LAR DEPOT (octreotide acetate for injectable suspension)
- Survivorship and Early Breast Cancer Information
- Symbyax® (Olanzapine and Fluoxetine HCl Capsules)
- TOVIAZ® (fesoterodine fumarate)
- Talecris Hypermunes™
- Targeted Biologic Therapy in Breast Cancer
- Targeting CD20: Scientific Insights and Implications for Therapy
- The HER signaling network and cancer
- The Pain Institute
- The Science of Facial Aging
- Treatment of Pulmonary Arterial Hypertension
- VESIcare (solifenacin succinate) tablets
- Vyvanse (lisdexamfetamine dimesylate)
- XYZAL® (levocetirizine dihydrochloride)
Advisory Board
- George S. Conomikes, BA, MA
- Jeffrey J. Denning
- Eric S. Fishman, MD
- Gregory A. Hood, MD
- Brian Kern, Esq.
- Kathryn I. Moghadas, RN, CLRM, CHBC, CPC, CHCC
- Joseph E. Scherger, MD, MPH
- Robert C. Scroggins, JD, CPA, CHBC
- Elizabeth Woodcock, MBA
Site Editorial Directors
Site Editor
